Treatment of dyslipidemia in patients with diabetes mellitus

Pharmacological Reports

Volumn 57, Issue SUPPL., 2005, Pages 10-19

  Pikto Pietkiewicz, Witold ^a   Wołkowska, Katarzyna ^a   Pasierski, Tomasz ^a  

^a Miedzyleski Central Hospital   (Poland)

Author keywords

Coronary artery disease; Diabetes mellitus; Diabetic dyslipidemia; Hypolipemic drugs

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; ATORVASTATIN; AVASIMIBE; CERIVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC VALUE; DRUG DOSE REGIMEN; DRUG POTENTIATION; DYSLIPIDEMIA; EATING HABIT; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POSTPRANDIAL STATE; PREDICTION; REVIEW; RISK FACTOR; SMOKING CESSATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 33645693626     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA, 2002,288,2998-2907.
2. Alsheikh-Ali AA, Karas RH: Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones. Am J Cardiol, 2004, 43, 1417-1418.
3. American Diabetes Association Standards of medical care in diabetes. ADA position statement. Diabetes Care, 2004, 27, Suppl 1, S15-35.
4. Anderson RA, Jones CHJ, Goodfellow J: Is the fatty meal a trigger for for acute coronary syndromes. Atherosclerosis, 2001, 159, 9-15.
5. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG: Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care, 2002, 25, 1198-1202.
6. Brouseau ME, Schaeffer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP et al.: Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol. N Engl J Med, 2004, 350, 1505-1515.
7. Brown AM, Gibbons GF: Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event. Arterioscler Thromb Vase Biol, 2001, 21, 1656-1661.
8. Cannon CP, Braunwald E, McCabe CH, Rder DJ, Rouleau JL, Belder R, Joyal SV et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N EngI J Med, 2004, 350, 1495-1504.
9. Ceriello A, Taboga C, Tonutti LI, Quagliaro L, Piconi L, Bais B, da Ros R et al.: Evidence for an independent and cumulative effect of postprandial hypertriglycerydemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation 2002, 106, 1211-1218.
10. Clark RW, Sutfin TA, Ruggeri RB: Villauer AT, Sugarman ED, Magnus-Aitcy G, Cosgrove PG et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vase Med, 2004, 24, 490-497.
11. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364, 685-696.
12. Collins R, Armitage J, Parish S, Sleigh P, Peto R: Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial. Lancet, 2003, 361, 2005-2016.
13. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S et al.: European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of european and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J, 2003, 24, 1601-1610.
14. Diabetes Atherosclerosis Intervention Study Investigators (no authors listed): Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet, 2001, 357, 905-910.
15. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA, 2000, 284, 1263-1270.
16. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
17. Frick MH, Elo O, Kappa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N EnglJ Med, 1987, 317, 1237-1245.
18. Golay A, Zech L, Shi MZ, Chiou A, Reaven GM, Chen YD: High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab, 1987, 65, 512-518.
19. Goldberg AC, Sapre A, Liu J, Capece I, Mitchel YB, Eztimibe Study Group: Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebocontrolled trial. Mayo Clin Proc, 2004, 79, 620-629.
20. Goldberg IJ, Kako Y, Lutz EP: Responses to eating: lipoproteins, lipolytic products and atherosclerosis. Curr Opin Lipidol, 2000, 11, 235-241.
21. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004, 110, 227-239.
22. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med, 1999, 159, 2661-2667.
23. Haffner SM: American Diabetes Association. ADA position statement Dyslipidemia management in adults with diabetes. Diabetes Care, 2004, 27, SuppI 1, S68-71.
24. Heine RJ, Dekker JM: Beyond posprandial hyperglycemia: metabolic factors associated with cardiovascular disease. Diabetologia, 2002, 45, 461-475.
25. Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, Yamazaki J et al.: Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol, 2004, 24, 558-563.
26. Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev, 2002, 23, 201-229.
27. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J or al.: Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia, 1997, 40, 454-A62.
28. Miettinen TA, Gylling H, Tuominen J, Simonen P, Koiviso V: Low synthesis and high absorption of cholesterol characterize type 1 diabetes. Diabetes Care, 2004, 27, 53-58.
29. Miettinen TA, Strandberg TE, Gyling H: Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol, 2000, 20, 1340-1346.
30. Pasternak RC, Smith SC Jr, Baircy-Merz; CN, Grundy SM, Cleeman JI, Lenefant C, American College of Cardiology, American Heart Association, National Heart, Lung and Blood Institute: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol, 2002, 40, 567-572.
31. Pietzsch J, Juselius U, Nitzsche S, Hanefeld M: In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes, 1998, 47, 1928-1934.
32. Pikto-Pietkiewicz W, Mamcarz A, Grzywanowska-Łaniewska I: Pathophysiology of disturbances of lipid metabolism in diabetes. Medipress-Kardiologia, 2003, 3, 3-9.
33. Pikto-Pietkiewicz W, Pasierski T: HDL lipoproteins: a new target of intervention in prevention of ischemic heart disease. In: Diabetokardiologia. Narkiewicz K, Pasierski T, Pikto-Pietkiewicz W, Strojek K, Medycyna Praktyczna, Kraków, 2004, 89.
34. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, Collins D et al.: Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care, 2003, 26, 1513-1517.
35. Rongen GA, Tack CJ: Triglycerides and endothelial function in type 2 diabetes. riglycerides and endothelial function in type 2 diabetes. Eur J Clin Invest, 2001, 31, 560-562.
36. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med, 2002, 162, 2597-2604.
37. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-1389.
38. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A et al.: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002, 287, 3215-3222.
39. Sever PS, Dahlof B, Poulter N, Wedel H, Collins R, Beevers G, Caulfield M et al.: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): Results in the subgroup of patients with diabetes. J Am Coll Cardiol, 2004, 43, A 882.
40. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002, 360, 1623-1630.
41. Simonen PP, Gylling HK, Miettinen TA: Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care, 2002, 25, 1511-1515.
42. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB: Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 2004, 140, 644-649.
43. Syvanne M, Abola M, Lahdenpera S, Kahri J, Kuusi T, Virtanen KS, Taskinen MR: High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res, 1995, 36,573-582.
44. Tardif JC, Gregoire J, Lesperance J, Lambert J, L'Allier PL, Rodes J, Anderson T et al.: Effects of avasimibe on coronary atherosclerosis assessed by intravascular ultrasound. J Am Coll Card, 2004, 43, A 882.
45. The FIELD study investigators. Effects of long-term fenofibrate therapy oncardJovascular events in 9795 people with trype 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet 2005, 366, 1849-1861.
46. Tomkin GH, Owens D: Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev, 2001, 17, 27-43.
47. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A et al.: Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation, 2003, 107, 1733-1737.
48. Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM: Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol, 2003, 91, 956-960.
49. Vijan S, Hayward RA. American College of Physicians: Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med, 2004, 140, 650-658.
50. Wanner C, Krane V, Matz W, Olschewski M, Mann JF, Ruf G, Ritz E et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med, 2005, 353, 238-248.